Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | Beyond anthracyclines and trastuzumab: cardiotoxicity of novel agents

Susan Dent • 6 Dec 2022
SABCS 2022
Breast Cancer Antibodies Pebrolizumab Ribociclib

The cardiotoxicity of anthracyclines and trastuzumab in the treatment of breast cancer have been well elucidated, however there is little information surrounding the cardiovascular impact for more recent novel agents. Susan Dent, MD, FRCPC, Duke University School of Medicine, Durham, NC, discusses the cardiovascular impact of newer novel agents including CDK4/6 inhibitors and immune checkpoint inhibitors. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Susan Dent

1:16
Key data at SABCS 2022
Susan Dent • 6 Dec 2022
4:30
ESC guidelines in cardio-oncology
Susan Dent • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals